Osimertinib patent expiry?

Osimertinib (Tagrisso) is protected by multiple patent families in different jurisdictions. Because there are several patents (compound/patent on the molecule itself, use/patient-subset patents, formulation patents, etc.) and because term extensions and regulatory data protections vary by country, the expiry date is not a single global date. In general:

- Core compound and key use patents are typically set to expire in the late 2020s to early 2030s in many major markets, but exact dates depend on:
- country-specific patent terms and extensions
- whether any additional (second‑use, formulation, or process) patents remain active
- regulatory data exclusivity and pediatric exclusivity (which can further delay generic entry)

If you want precise expiry dates for a specific country or region, I can help you look them up. Tell me which country(s) you’re interested in, and I’ll outline the relevant patent families and their current status (with approximate expiry dates). If you’d prefer, I can also guide you through checking yourself on public patent databases (e.g., Google Patents, Espacenet, USPTO/Orange Book for the US, EUIPO/Espacenet for the EU).